245 related articles for article (PubMed ID: 26712693)
1. Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells.
Zhang W; Yi B; Wang C; Chen D; Bae S; Wei S; Guo RJ; Lu C; Nguyen LL; Yang WH; Lillard JW; Zhang X; Wang L; Liu R
Clin Cancer Res; 2016 May; 22(10):2545-54. PubMed ID: 26712693
[TBL] [Abstract][Full Text] [Related]
2. A CD24-p53 axis contributes to African American prostate cancer disparities.
Liu W; Zhang Y; Wei S; Bae S; Yang WH; Smith GJ; Mohler JL; Fontham ETH; Bensen JT; Sonpavde GP; Chen GY; Liu R; Wang L
Prostate; 2020 May; 80(8):609-618. PubMed ID: 32168400
[TBL] [Abstract][Full Text] [Related]
3. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
[TBL] [Abstract][Full Text] [Related]
4. Intracellular CD24 disrupts the ARF-NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation.
Wang L; Liu R; Ye P; Wong C; Chen GY; Zhou P; Sakabe K; Zheng X; Wu W; Zhang P; Jiang T; Bassetti MF; Jube S; Sun Y; Zhang Y; Zheng P; Liu Y
Nat Commun; 2015 Jan; 6():5909. PubMed ID: 25600590
[TBL] [Abstract][Full Text] [Related]
5. ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylation.
Morton DJ; Patel D; Joshi J; Hunt A; Knowell AE; Chaudhary J
Oncotarget; 2017 Jan; 8(2):2536-2549. PubMed ID: 27911860
[TBL] [Abstract][Full Text] [Related]
6. Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of
Guedes LB; Almutairi F; Haffner MC; Rajoria G; Liu Z; Klimek S; Zoino R; Yousefi K; Sharma R; De Marzo AM; Netto GJ; Isaacs WB; Ross AE; Schaeffer EM; Lotan TL
Clin Cancer Res; 2017 Aug; 23(16):4693-4703. PubMed ID: 28446506
[No Abstract] [Full Text] [Related]
7. Mutant TP53 G245C and R273H promote cellular malignancy in esophageal squamous cell carcinoma.
Kang N; Wang Y; Guo S; Ou Y; Wang G; Chen J; Li D; Zhan Q
BMC Cell Biol; 2018 Aug; 19(1):16. PubMed ID: 30126368
[TBL] [Abstract][Full Text] [Related]
8. The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53.
Bajgelman MC; Strauss BE
Prostate; 2006 Sep; 66(13):1455-62. PubMed ID: 16741917
[TBL] [Abstract][Full Text] [Related]
9. RNA interference targeting mutant p53 inhibits growth and induces apoptosis in DU145 human prostate cancer cells.
Zhu H; Mao Q; Lin Y; Yang K; Xie L
Med Oncol; 2011 Dec; 28 Suppl 1():S381-7. PubMed ID: 20857345
[TBL] [Abstract][Full Text] [Related]
10. CD24 is a genetic modifier for risk and progression of prostate cancer.
Zhang Y; Li B; Zhang X; Sonpavde GP; Jiao K; Zhang A; Zhang G; Sun M; Chu C; Li F; Wang L; Cui R; Liu R
Mol Carcinog; 2017 Feb; 56(2):641-650. PubMed ID: 27377469
[TBL] [Abstract][Full Text] [Related]
11. Effect of p53 gene polymorphism on functions of prostate cancer cells.
Chi N; Yun ZZ; Tan ZH; Li XZ; Chen BT; Liu J; Xu LB; Ma KW; Li SX; Liu JF; Liu CX
Genet Mol Res; 2015 Oct; 14(4):11700-9. PubMed ID: 26436494
[TBL] [Abstract][Full Text] [Related]
12. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
Cui B; Yang Q; Guan H; Shi B; Hou P; Ji M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E962-70. PubMed ID: 24512488
[TBL] [Abstract][Full Text] [Related]
13. Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis.
Weng CC; Ding PY; Liu YH; Hawse JR; Subramaniam M; Wu CC; Lin YC; Chen CY; Hung WC; Cheng KH
Oncogene; 2019 Mar; 38(12):2005-2019. PubMed ID: 30467381
[TBL] [Abstract][Full Text] [Related]
14. PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis.
Zaza M; Rashed MH; Elrefaey H; Hassan MH; Abo-Salem OM; El-Sayed ESM
Can J Physiol Pharmacol; 2024 Jan; 102(1):55-68. PubMed ID: 37818839
[TBL] [Abstract][Full Text] [Related]
15. Id4 dependent acetylation restores mutant-p53 transcriptional activity.
Knowell AE; Patel D; Morton DJ; Sharma P; Glymph S; Chaudhary J
Mol Cancer; 2013 Dec; 12():161. PubMed ID: 24330748
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis.
Lambert JM; Moshfegh A; Hainaut P; Wiman KG; Bykov VJ
Oncogene; 2010 Mar; 29(9):1329-38. PubMed ID: 19946333
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
[TBL] [Abstract][Full Text] [Related]
19. Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo.
Gu J; Wang B; Liu Y; Zhong L; Tang Y; Guo H; Jiang T; Wang L; Li Y; Cai L
Eur J Cancer; 2014 Apr; 50(6):1184-94. PubMed ID: 24447832
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 and mTOR/PKM2 regulation in cancer cells.
Dando I; Cordani M; Donadelli M
IUBMB Life; 2016 Sep; 68(9):722-6. PubMed ID: 27385486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
